) presented promising data on Cinryze at the American College of
Allergy, Asthma and Immunology's (ACAAI) annual congress. Data
was presented from a post marketing study that evaluated the
safety, tolerability and efficacy of Cinryze in escalating doses
in patients with hereditary angioedema (HAE), who did not show
sufficient treatment benefit with 1000 units every 3 or 4 days.
HALOZYME THERA (HALO): Free Stock Analysis
VIROPHARMA (VPHM): Free Stock Analysis Report
To read this article on Zacks.com click here.
The open-label multicenter study enrolled 20 patients over a span
of 3 years. It was observed that doses up to 2500 units every 3
or 4 days can be prescribed to patients who show insufficient
response to bi-weekly 1000 units. Additionally, Cinryze was found
to be well tolerated and side effects observed were consistent
with previous studies.
We note that Cinryze is approved both in the US and Europe. In
the US, the drug is approved for routine prophylaxis against
angioedema attacks in adolescent and adult patients with HAE. In
Europe, it is approved for routine prevention, pre-procedure
prevention and acute treatment of angioedema attacks in
adolescent and adult patients with HAE.
The company is also evaluating the subcutaneous administration of
Cinryze in combination with its partner,
) recombinant human hyaluronidase enzyme (rHuPH20). In September
2012, the US Food and Drug Administration (FDA) removed a
clinical hold on the phase II study. The company plans to
initiate a phase II study in the EU shortly.
In the third quarter of 2012, Cinryze's net sales climbed 30.4%
y/y to $85.3 million, driven by higher demand. Bulk of the sales
($84 million) came from the US. US sales were reflective of
patient demand ($82 million) and inventory build up ($2 billion),
according to management.
We currently have a Neutral recommendation on ViroPharma. The
stock carries a Zacks #3 Rank (Hold rating) in the short run.
We are encouraged by Cinryze's sales growth and patient additions
in the third quarter of 2012. However, we remain concerned about
the lack of late-stage pipeline candidates and the company's
dependency on Cinryze for growth.